3 / 10
Page 39
E u r o p e a n C o n g r e s s o n
Vaccines & Vaccination
and Gynecologic Oncology
Vaccines & Vaccination and Gynecologic Oncology 2018
O c t o b e r 2 6 - 2 7 , 2 0 1 8
B u d a p e s t , H u n g a r y
Critical Care Obstetrics and Gynecology
ISSN: 2471-9803
The selective effect of NSC-631570 on women reproductive cancers
Wassil Nowicky
Nowicky Pharma/ Ukrainian Anti-Cancer Institute, Austria
Biography
Wassil Nowicky (Dipl Ing, Dr techn, DDD rh c) is the Director of
Nowicky Pharma and President of the Ukrainian Anti-Cancer
Institute (Vienna, Austria). He has finished his study at the Ra-
diotechnical Faculty of the Technical University of Lviv (Ukraine)
with the end of 1955, with graduation to “Diplomingeniueur”
in 1960 which title was nostrificated in Austria in 1975. He
became the very first Scientist in the development of the anti-
cancer protonic therapy and is the Inventor of NSC-631570, the
anticancer preparation on basis of celandine alkaloids. He used
the factor that cancer cells are more negatively charged than
normal cells and invented the celandine alkaloid with a positive
charge, thanks to which it accumulates in cancer cells very fast.
He is the Author of over 300 scientific articles dedicated to can-
cer research. He is a real Member of the New York Academy
of Sciences, Member of the European Union for applied immu-
nology and of the American Association for scientific progress,
honorary Doctor of the Yanka Kupala State University of Grod-
no, Doctor Honoris Causa of the Open International University
for Complementary Medicine in Colombo, Honorary Member of
the Austrian Society on the Name of Albert Schweizer. He has
received merits of National Guild of the award of Austrian Soci-
ety of sanitary, hygiene and public health services and others.
dr.nowicky@yahoo.deF
irst indications on the selective effect of NSC‐631570 on the cancer cells were
provided in an early study when different oxygen consumption by normal liver
cells and Ehrlich’s tumor ascitic cells after the incubation with NSC‐631570 was
re-vealed. In the tests on the Jurkat lympho-ma model, NSC‐631570 has been
proven to be a strong apoptosis inductor. Profound research showed NSC‐631570
brought about the depolarization of mitochondrial membranes and consequently
the activation of caspases. NSC‐631570 induced apoptosis in a panel of cancer
cell lines (ovarial and cervical cancer HeLa, HeKB, HeKS32, HeBcl3, HeNFR
and HeIKK, human colon cancer SW480, human renal carcinoma HEK293,
human osteosarcoma MG‐63) by activating the caspases of the intrinsic cell
death pathway. Interestingly, non‐transformed fibroblasts (hTERT) cell line was
insensitive to the drug. In the tests on human ovarian and cervix carcinoma cells
HeLa, squamous carcinoma cells WHCO5, normal kidney cell line Graham 293,
and transformed kidney cell line Vero from African green monkey, NSC‐631570
inhibited the tubulin polymerisation and caused a metaphase block in cancer cells
which is characterized by abnormal chromosomal distribution, and results in the
formation of micronuclei and in apoptosis.
Wassil Nowicky, Crit Care Obst & Gyne 2018, Volume: 4
DOI:10.21767/2471-9803-C1-002